CLINICAL EFFECT OF NEOADJUVANT CHEMOTHERAPY IN THE TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER

Abstract Objectives Breast cancer, as one of the malignant tumor diseases that endanger the physical health of women worldwide nowadays, has a relatively high incidence and mortality rate. This study analyzed the clinical effect of neoadjuvant chemotherapy with paclitaxel plus carboplatin in patients with triple-negative breast cancer. Methods A retrospective analysis was conducted on 70 patients with triple-negative breast cancer admitted to our hospital. Among them, 35 patients received neoadjuvant chemotherapy with paclitaxel + anthracyclines (group A), and 35 patients received neoadjuvant chemotherapy with paclitaxel + carboplatin (group B). The quality of life, clinical efficacy and incidence of adverse reactions of the two groups were compared. Results After the treatment, the quality of life in group B was higher than that in group A (p<.01). The overall response rate in group B was higher than that in group A (p<.05). Both groups presented adverse reactions such as nausea and vomiting, alopecia, leukopenia, abnormal liver function, and diarrhea. There was no significant difference in the incidence of adverse reactions between the two groups (p>.05). Conclusions Neoadjuvant chemotherapy with paclitaxel + carboplatin can effectively increase the overall response rate, improve the quality of life, enhance the chemotherapy effect of triple-negative breast cancer, and has clinical application prospects.